Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent, Clive S. 1; Taylor, Ronald P. 2; Lindorfer, Margaret A. 2; Beum, Paul V. 2; LaPlant, Betsy 3; Wu, Wenting 3; Call, Timothy G. 1; Bowen, Deborah A. 1; Conte, Michael J. 1; Frederick, Lori A. 4; Link, Brian K. 5; Blackwell, Sue E. 5; Veeramani, Suresh 5; Baig, Nisar A. 1; Viswanatha, David S. 4; Weiner, George J. 5; Witzig, Thomas E. 1,*
American Journal Of Hematology.
89(7):757-765, July 2014.
(Format: HTML, PDF)